Recent advances of immunotherapy for biliary tract cancer
A Rizzo, AD Ricci, G Brandi - Expert review of gastroenterology & …, 2021 - Taylor & Francis
Introduction: Biliary tract cancer (BTC) is a heterogeneous group of aggressive malignancies
comprising intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder …
comprising intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder …
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: Evidence to date and future perspectives
A Rizzo, AD Ricci, G Brandi - Expert Opinion on Investigational …, 2021 - Taylor & Francis
ABSTRACT Introduction Biliary tract cancers (BTCs) are poor prognosis malignancies
usually classified in intrahepatic cholangiocarcinoma (iCCA), extrahepatic …
usually classified in intrahepatic cholangiocarcinoma (iCCA), extrahepatic …
[HTML][HTML] First-line chemotherapy in advanced biliary tract cancer ten years after the ABC-02 trial:“And yet it moves!”
A Rizzo, G Brandi - Cancer treatment and research communications, 2021 - Elsevier
Biliary tract cancers (BTCs) include a heterogeneous group of highly aggressive
hepatobiliary malignancies, representing the 3% of all gastrointestinal cancers and the …
hepatobiliary malignancies, representing the 3% of all gastrointestinal cancers and the …
[HTML][HTML] Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma
A Rizzo, AD Ricci, G Brandi - Cancer Treatment and Research …, 2021 - Elsevier
Cholangiocarcinoma (CCA) includes a heterogeneous group of malignancies with limited
treatment options. Despite recent advances in medical oncology, the prognosis of CCA …
treatment options. Despite recent advances in medical oncology, the prognosis of CCA …
Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer
A Rizzo, G Brandi - Expert review of gastroenterology & hepatology, 2021 - Taylor & Francis
Introduction: Unfortunately, potentially curative surgical resection is possible in
approximately the 25% of biliary tract cancer (BTC) patients at diagnosis, and even following …
approximately the 25% of biliary tract cancer (BTC) patients at diagnosis, and even following …
Ampullary carcinoma: an overview of a rare entity and discussion of current and future therapeutic challenges
A Rizzo, V Dadduzio, L Lombardi, AD Ricci… - Current …, 2021 - mdpi.com
Ampullary carcinomas (ACs) represent a rare entity, accounting for approximately 0.2% of all
gastrointestinal solid tumors and 20% of all periampullary cancers (PACs). Unfortunately …
gastrointestinal solid tumors and 20% of all periampullary cancers (PACs). Unfortunately …
ESMO scale for clinical actionability of molecular targets driving targeted treatment in patients with cholangiocarcinoma
H Verdaguer, T Saurí, DA Acosta, M Guardiola… - Clinical Cancer …, 2022 - AACR
Purpose: Treatment options for advanced cholangiocarcinoma are limited and prognosis is
poor. Cholangiocarcinomas are highly heterogeneous at the molecular level, with divergent …
poor. Cholangiocarcinomas are highly heterogeneous at the molecular level, with divergent …
Immunotherapy in biliary tract cancer: worthy of a second look
AD Ricci, A Rizzo, G Brandi - Cancer control, 2020 - journals.sagepub.com
Although immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape of
several malignancies, the role of immunotherapy in biliary tract cancer (BTC) is currently …
several malignancies, the role of immunotherapy in biliary tract cancer (BTC) is currently …
Feasibility and tolerability of sintilimab plus anlotinib as the second‐line therapy for patients with advanced biliary tract cancers: An open‐label, single‐arm, phase II …
S Jin, R Zhao, C Zhou, Q Zhong, J Shi… - … Journal of Cancer, 2023 - Wiley Online Library
Patients with biliary tract cancer (BTC) were associated with poor prognosis and limited
therapeutic options after first‐line therapy currently. In this study, we sought to evaluate the …
therapeutic options after first‐line therapy currently. In this study, we sought to evaluate the …
Hematological toxicities in PARP inhibitors: a real‐world study using FDA adverse event reporting system (FAERS) database
Y Shu, Y Ding, X He, Y Liu, P Wu, Q Zhang - Cancer medicine, 2023 - Wiley Online Library
Objective Poly ADP‐ribose polymerase inhibitors (PARPis) have significantly improved
clinical effects in gynecological oncology. However, PARPis could also induce severe organ …
clinical effects in gynecological oncology. However, PARPis could also induce severe organ …